Efficacy and safety of celecoxib for treatment of mild to moderate postpartum depression: a randomized, double-blind, placebo-controlled trial

Esalatmanesh, Sophia; Kashani, Ladan; Khooshideh, Maryam; Moghaddam, Hossein Sanjari; Ansari, Sahar; Akhondzadeh, Shahin

doi:10.1007/s00404-023-07042-4

Cited by 4 publications

(2 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, it has been reported that elevated plasma levels of inflammatory markers (IL-1 and IL-6) in older individuals are predictive of the development of depressive symptoms over a 6-year period [ 7 ]. In addition, the efficacy of celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), in ameliorating postpartum depressive symptoms has been established [ 8 ]. Therefore, the potential correlation between inflammation and depression presents an avenue for addressing the latter through the implementation of anti-inflammatory strategies that target the immune system.…”

Section: Introductionmentioning

confidence: 99%

Effect of duloxetine on changes in serum proinflammatory cytokine levels in patients with major depressive disorder

Gao,

et al. 2024

BMC Psychiatry

View full text Add to dashboard Cite

Objective Accumulating evidence supports the idea that inflammation may contribute to the pathophysiology of major depressive disorder (MDD). Duloxetine, a serotonin-norepinephrine reuptake inhibitor, exhibits anti-inflammatory effects both in vitro and in vivo. In this study, we investigated the impact of duloxetine on changes in serum proinflammatory cytokine levels among individuals diagnosed with MDD. Methods A cohort of 23 drug-naïve individuals diagnosed with MDD and 23 healthy controls were included in this study. The severity of depressive symptoms was evaluated using the 24-item Hamilton Depression Scale (HAMD-24). A panel of 7 proinflammatory cytokines, including interleukin-1β (IL-1β), IL-2, IL-6, IL-8, IL-12, tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ), were quantified using multiplex Luminex assays. The levels of serum cytokines in healthy controls and patients with MDD were compared at baseline. All patients received duloxetine at a dosage range of 40–60 mg/day for a duration of 4 weeks. The HAMD-24 scores and serum cytokine levels were compared before and after duloxetine treatment. Results Compared with healthy controls, patients with MDD had significantly greater levels of IL-2, IL-6, IL-8, IL-12, TNF-α, and IFN-γ (P < 0.05). Moreover, there was a significant decrease in HAMD-24 scores observed pre- and post-treatment (t = 13.161, P < 0.001). Furthermore, after 4 weeks of treatment, the serum levels of IL-8 (t = 3.605, P = 0.002), IL-12 (t = 2.559, P = 0.018), and IFN-γ (t = 3.567, P = 0.002) decreased significantly. However, there were no significant differences in other cytokines, including IL-1β, IL-2, IL-6, and TNF-α, before and after treatment (P > 0.05). Conclusions These findings present compelling evidence, potentially for the first time, indicating that duloxetine treatment may effectively reduce the serum concentrations of IL-8, IL-12, and IFN-γ in individuals diagnosed with MDD. However, the precise mechanisms underlying this effect remain unclear and warrant further investigation.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of duloxetine on changes in serum proinflammatory cytokine levels in patients with major depressive disorder

Gao,

et al. 2024

BMC Psychiatry

View full text Add to dashboard Cite

show abstract

“…Due to its role in depressive neuroprogression generally, immune-metabolic dysregulation is also increasingly implicated in a subset of treatment-refractory forms of depressive illness [ 1 , 8 , 9 ]. In that vein, several randomized control trials (RCTs) have established preliminary support for adjunctive anti-inflammatory treatment in treatment-resistant depression [ 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 ]. In a recent double-blind, placebo-controlled RCT in treatment-resistant bipolar depression (TRBDD), we demonstrated that clinical remission can be induced with adjunctive immune modulatory treatment with the selective cyclo-oxygenase 2 (COX2) inhibitor, celecoxib (CBX), in conjunction with an adequately dosed selective serotonin reuptake inhibitor (SSRI), escitalopram (ESC) [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Systemic Inflammatory Response Index (SIRI) at Baseline Predicts Clinical Response for a Subset of Treatment-Resistant Bipolar Depressed Patients

Murata,

Baig,

Decker

et al. 2023

JPM

View full text Add to dashboard Cite

Background: in a recent double-blind, placebo controlled RCT we demonstrated that selective inhibition of cyclo-oxygenase 2 (COX2) is an effective adjunctive strategy in treatment-resistant bipolar depression (TRBDD). To better clarify the mechanisms underlying TRBDD and treatment response, we conducted a retrospective exploratory analysis of the systemic inflammatory response index (SIRI = absolute neutrophils × absolute monocytes/absolute lymphocytes) in relation to other biomarkers and clinical outcomes after escitalopram (ESC), combined with the COX-2 inhibitor, celecoxib (CBX), versus placebo. Methods: Baseline measures of SIRI were compared between TRBDD and healthy controls (HC), and correlated with blood-based inflammatory cytokines, kynurenines, and growth factors. Post-treatment Hamilton Depression Rating Scale 17 (HAMD-17) total scores (clinical outcome) were modelled according to SIRI adjusting for demographics (including relevant interactions with SIRI), baseline depression, treatment arm, and treatment timepoint using multiple linear regression and robust linear mixed effects models. Results: Baseline SIRI did not distinguish TRBDD from HC groups. Baseline SIRI was significantly correlated with lower baseline MCP-1. The relationship between SIRI and HAMD-17 was significant at treatment week 8, in contrast to baseline. Finally, baseline SIRI predicted elevated post-treatment HAMD-17 scores, amongst patients with elevated depression scores at baseline. Significance: High pre-treatment SIRI may predict poorer depressive outcomes amongst TRBDD patients with baseline elevated depression.

show abstract

Perioperative esketamine administration for prevention of postpartum depression after the cesarean section: A systematic review and meta-analysis

Parsaei,

Hasehmi,

Seyedmirzaei

et al. 2024

Journal of Affective Disorders

View full text Add to dashboard Cite

Efficacy and safety of celecoxib for treatment of mild to moderate postpartum depression: a randomized, double-blind, placebo-controlled trial

Cited by 4 publications

References 47 publications

Effect of duloxetine on changes in serum proinflammatory cytokine levels in patients with major depressive disorder

Effect of duloxetine on changes in serum proinflammatory cytokine levels in patients with major depressive disorder

Systemic Inflammatory Response Index (SIRI) at Baseline Predicts Clinical Response for a Subset of Treatment-Resistant Bipolar Depressed Patients

Perioperative esketamine administration for prevention of postpartum depression after the cesarean section: A systematic review and meta-analysis

Contact Info

Product

Resources

About